Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Neuphoria Therapeutics to similar businesses based on the strength of its valuation, profitability, institutional ownership, risk, earnings, analyst recommendations and dividends.
Analyst Recommendations
This is a breakdown of current ratings for Neuphoria Therapeutics and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuphoria Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Neuphoria Therapeutics Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Neuphoria Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 197.87%. As a group, “Biotechnology” companies have a potential upside of 114.69%. Given Neuphoria Therapeutics’ higher possible upside, equities research analysts clearly believe Neuphoria Therapeutics is more favorable than its rivals.
Volatility and Risk
Profitability
This table compares Neuphoria Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuphoria Therapeutics | N/A | -2.74% | -2.31% |
| Neuphoria Therapeutics Competitors | -12,519.20% | -215.47% | -31.42% |
Insider & Institutional Ownership
15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Neuphoria Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Neuphoria Therapeutics | $1.17 million | -$13.45 million | -0.38 |
| Neuphoria Therapeutics Competitors | $704.12 million | $8.07 million | -17.98 |
Neuphoria Therapeutics’ rivals have higher revenue and earnings than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Neuphoria Therapeutics rivals beat Neuphoria Therapeutics on 7 of the 13 factors compared.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
